ESR1 and breast cancer: In contrast, the American Society of Clinical Oncology guidelines state that the clinician should not use the 21-gene RS to guide therapy in node positive ER+/HER2− breast cancer.23 While prospective clinical trials are ongoing to answer this question, these disparate recommendations may lead to confusion among patients and providers and thus impact reimbursement by payers.22